every step counts
NUROWN UPDATE
BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program
NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial.
NEWS

PROMISING PATHWAY ACT
July 12, 2020
Take action to pass this bill
Take 30 seconds out of your day to help build Congress support